Abstract | BACKGROUND: PATIENT FINDINGS: SUMMARY: A TRIAC pharmacokinetic study, conducted using triiodothyronine level as a surrogate for TRIAC level, demonstrated that TRIAC disappears from the circulation rapidly and has a shorter duration of TSH secretion inhibitory effect in the RTH patient compared to that in the control subject. Studies of TSH and FT4 levels over a period of 3 years indicated that the TRIAC effect is dose dependent. CONCLUSIONS:
TRIAC was effective and safe in ameliorating the effects of hyperthyroidism and ADHD symptoms in a child with known genetic RTH. Further, it was demonstrated that TRIAC has a short half-life and functions dose dependently.
|
Authors | Rie Anzai, Masanori Adachi, Noriko Sho, Koji Muroya, Yumi Asakura, Kazumichi Onigata |
Journal | Thyroid : official journal of the American Thyroid Association
(Thyroid)
Vol. 22
Issue 10
Pg. 1069-75
(Oct 2012)
ISSN: 1557-9077 [Electronic] United States |
PMID | 22947347
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Thyroid Hormone Receptors beta
- Triiodothyronine
- 3,3',5-triiodothyroacetic acid
- Thyrotropin
- Thyroxine
|
Topics |
- Adolescent
- Adult
- Atrial Premature Complexes
(drug therapy)
- Attention Deficit Disorder with Hyperactivity
(drug therapy)
- Child
- Child, Preschool
- Female
- Half-Life
- Humans
- Hyperthyroidism
(drug therapy)
- Male
- Thyroid Hormone Receptors beta
(genetics)
- Thyroid Hormone Resistance Syndrome
(drug therapy)
- Thyrotropin
(blood)
- Thyroxine
(blood)
- Triiodothyronine
(administration & dosage, analogs & derivatives, blood, pharmacokinetics, therapeutic use)
|